Erhalte eine Antwort von diesem Arbeitgeber
Dein Lebenslauf und dein Anschreiben, genau auf das zugeschnitten, was gesucht wird.
Sapienza Università di Roma, Dipartimento di Medicina Molecolare, cerca un ricercatore per una posizione di ricerca avanzata su TNBC e meccanismi di progressione tumorale. Il progetto esamina la suscettibilità a chemioterapici (carboplatino) e PARP inibitori e l’impatto di MAML1 sulla sopravvivenza cellulare in condizioni di stress terapeutico.
La selezione prevede qualifiche e colloquio; dettagli nel bando.
Organisation/Company Dipartimento di Medicina Molecolare- Sapienza università di Roma Research Field Medical sciences » Medicine Researcher Profile Recognised Researcher (R2) Leading Researcher (R4) First Stage Researcher (R1) Established Researcher (R3) Application Deadline 23 Nov 2026 - 23:59 (UTC) Country Italy Type of Contract To be defined Job Status Not Applicable Is the job funded through the EU Research Framework Programme? Not funded by a EU programme Is the Job related to staff position within a Research Infrastructure? No
Triple-negative breast cancer (TNBC) is a highly aggressive tumor subtype, characterized by early onset, high metastatic capacity, and a high recurrence rate, representing a significant clinical challenge. Currently, platinum-based chemotherapy and PARP inhibitors (indicated in tumors with BRCA1/2 gene mutations) are the mainstay of systemic treatment aimed at inducing DNA damage and replicative stress. However, a significant proportion of patients show primary or acquired resistance to such treatments. In this context, the MAML1 protein emerges as a potential key regulator of tumor progression. Preliminary data indicate that MAML1 may support cell survival and proliferation under conditions of carboplatin- or olaparib-induced therapeutic stress, promoting DNA damage repair mechanisms.
Qualifications and interview. See detail in the call